No Data
No Data
Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $42
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corbus Pharmaceuticals (CRBP), Genmab (GMAB) and CVRx (CVRX)
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 From Western Dose Escalation Study to Be Presented at 2025 ASCO-GU
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $75
Express News | HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Lowers Price Target to $75
J L 7 2 : Now even good news is of no use, the stock price is plummeting
.